Stockpolly
Search
DERM · NASDAQ · Drug Manufacturers - Specialty & Generic

Journey Medical (DERM)

Markets prescription dermatology medicines through a focused U.S. sales organization.

$7.85
Pre-market+0.07 (+0.90%)
At close$7.78(+2.77%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue351513151514131518161619
Cost of revenue667752666776
Gross profit28968911791210912
11111611129111213101012
Research & development228110000000
910810111011120101011
Selling & marketing0−20000000000
General & administrative01200000000011
Other expenses00000−10013001
Operating income17−2−10−3−32−3−3−20−10
00001−1−1−1−1−1−1−1
Interest income000000000000
Interest expense001111111111
Other non-operating income0000−10000000
Income before tax17−2−10−3−22−4−4−2−1−20
Income tax expense000000000000
Net income from continuing operations17−2−10−3−22−4−4−2−1−20
Net income17−2−10−3−22−4−4−2−1−20
EPS, basic$0.91−$0.11−$0.53−$0.17−$0.12$0.07−$0.18−$0.16−$0.09−$0.05−$0.08−$0.01
EPS, diluted$0.80−$0.11−$0.53−$0.17−$0.12$0.07−$0.18−$0.16−$0.09−$0.05−$0.08−$0.01
Weighted average shares, basic181920202122232325242727
Weighted average shares, diluted211920202122232325242727
EBITDA18−1−9−2−13−2−20102
Depreciation & amortization111111111111
EBIT17−2−10−3−22−3−3−10−11